Albany Molecular Research (AMRI)
Your Dashboard
Displaying AMRI Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 25.00M
- Accounts Receivable 47.49M
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.7114
- Beneish M-Score Pro
- Beta Pro
- Book Value 205.35M
- Book Value per Share 6.674
- Capital Expenditures 2.105M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing -4.673M
- Cash Financing TTM -6.214M
- Cash Investing -2.023M
- Cash Investing TTM 2.859M
- Cash Operations -5.68M
- Cash Operations TTM 3.06M
- Cash and Equivalents 8.244M
- Cash and ST Investments 12.75M
- Current Ratio 2.646
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.0265
- Dividend
- Dividend Yield 0.00%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share -0.13
- Earnings Per Share Growth
- Earnings Per Share TTM -1.16
- Earnings Yield -42.80%
- Effective Tax Rate TTM Pro
- Enterprise Value 80.58M
- Expenses 57.50M
- Expenses TTM 239.03M
- Free Cash Flow -7.785M
- Free Cash Flow TTM -7.521M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 24.07%
- Gross Profit TTM 34.54M
- Income from Cont. Ops Pro
- Interest Expense 0.142M
- Interest Income
- Inventories 29.31M
- KZ Index Pro
- Liabilities 58.02M
- Long Term Debt 5.441M
- Market Cap 83.39M
- Net Income -3.807M
- Net Income TTM -34.64M
- Net PP&E 145.05M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price 2.71
- Price / Book Value 0.4061
- Price / Sales Ratio 0.408
- Price / Tangible Book Value Pro
- Profit Margin -7.09%
- R&D Expense 0.373M
- Receivables Turnover 4.196
- Retained Earnings 75.15M
- Retained Earnings Growth -31.55%
- Return on Assets -11.91%
- Return on Equity -15.20%
- Return on Invested Capital Pro
- Revenue Growth -5.71%
- Revenue Per Share TTM 6.643
- Revenues 53.70M
- Revenues TTM 204.39M
- SG&A Expense 9.846M
- Shareholders Equity 205.35M
- Shares Outstanding 30.77M
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 263.37M
- Total Return Price 2.71
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these AMRI related companies
AMRI News
Listen to $AMRI Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3k43
about 18 days ago by earningscast
about 18 days ago by earningscast
I need all the ones that horizon Alerted recently that im currently stuck in way down $RCON $AMRI $NFC $SINO and more to go up a lot
about 23 days ago by epime7heus
about 23 days ago by epime7heus
AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services
Apr 30, 8:00AM PR Newswire
Apr 30, 8:00AM PR Newswire
AMRI Announces Development and Manufacturing Deal with Biota Holdings Limited
Apr 17, 8:00AM PR Newswire
Apr 17, 8:00AM PR Newswire
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
Apr 03, 8:01AM Benzinga
Apr 03, 8:01AM Benzinga
AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations
Mar 27, 8:00AM PR Newswire
Mar 27, 8:00AM PR Newswire
Albany Molecular Research (AMRI) Reports Q4 Loss of $0.19; Guides Contract Revs
Feb 07, 8:05AM Street Insider
Feb 07, 8:05AM Street Insider
AMRI CFO to Present at UBS 22nd Annual Global Healthcare Services Conference
Feb 01, 8:00AM PR Newswire
Feb 01, 8:00AM PR Newswire
Albany Molecular (AMRI) Announces Workforce Reduction, to Cease Facility Lease; Updates on Expected Charges
Dec 22, 5:08PM Street Insider
Dec 22, 5:08PM Street Insider
Insider Cluster-Buying At $AMRI. 23,900 shares purchased. http://stks.co/1Xse
about 165 days ago by abubnic
about 165 days ago by abubnic
Sterne Agee reiterated its “Buy” rating on $AMRI with a price target of $7.00.
about 165 days ago by abubnic
about 165 days ago by abubnic
$AMRI $5.00 Hagen Steven R officer (VP Pharmaceutical Dev & Mfg) S 198 @ $4.84 amnt $958 proc'd ($32) 5/6/2011
about 381 days ago by canarionyc
about 381 days ago by canarionyc
$AMRI http://chart.ly/xvpba4r Closed above 50 day on high volume, 10% of float is short, MACD looks ready
about 405 days ago by Tr8r_x
about 405 days ago by Tr8r_x
$AMRI Hagen Steven R officer (VP Pharmaceutical Dev & Mfg) sold 2,000 @ $5.20 totl $10,400.00 2010-12-06
about 524 days ago by canarionyc
about 524 days ago by canarionyc
start swing long 1k $AMRI on long time coming trend reversal, looking for 6.3 stop 5.3
about 709 days ago by Assailed
about 709 days ago by Assailed
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMRI | 2.71 | -0.05 | -1.81% | 83.39M |
| AMRC | 11.07 | -0.15 | -1.34% | 289.15M |
| AMPL | 0.185 | +0.01 | +2.83% | 10.38M |
| ALVR | 0.49 | +0.03 | +6.52% | 28.41M |
| ALV | 57.16 | -0.25 | -0.44% | 5.116B |
| ALU | 1.67 | +0.07 | +4.38% | 3.883B |
| ALTR | 34.42 | +0.66 | +1.96% | 11.11B |
| ALTI | 0.66 | +0.00 | +0.00% | 45.84M |
| ALTH | 1.80 | +0.00 | +0.00% | 192.53M |
| ALTE | 22.72 | -0.28 | -1.22% | 2.292B |
